Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
Conditions
Keywords
AMN, XALD
Brief summary
Subjects will be administered multiple doses of VK0214 in a cohort dose escalation process. A total of up to 36 subjects will be enrolled in the study, into one of three dose cohorts. For each cohort, up to 12 subjects will be randomized to receive VK0214 or placebo in a 3:1 ratio so that there will be a total of up to 9 subjects for each of the active doses and up to 3 subjects dosed with placebo in each cohort.
Detailed description
The first part of VK0214-102 will include the first 2 dose cohorts and placebo, which will be dosed in parallel (up to N=24). The first 2 doses used in these cohorts will be 20 mg QD and 40 mg QD for 28 days. A Dose Level Review Team (DLRT) meeting will be held at the end of the first 2 parallel doses. The DLRT will review safety, tolerability, and preliminary efficacy data from cohort 1 and 2. If the data analyzed show that the first 2 doses are safe and well tolerated the DLRT may make a recommendation for proceeding to commence dosing in the third dose cohort. Based upon outcomes in Cohorts 1 and 2, the sponsor may decide to include a third dose cohort. Before screening may be initiated in Cohort 3, data to support dosing in this cohort will be submitted to the FDA, together with the amended protocol and the dosing recommendation of the DLRT.
Interventions
DRUGVK0214
API in capsule
OTHERPlacebo
API in capsule
Sponsors
Viking Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provide a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study and is willing and able to participate. * Have diagnosis of X-linked adrenoleukodystrophy (X-ALD) by genetic testing and elevated VLCFAs. * Present clinical features of AMN, or adrenal insufficiency. * Subjects must be 18 years of age and older.
Exclusion criteria
* Have the cerebral form of X-ALD, based on medical records, or based on MRI performed within the last 12 months or MRI at screening * Have been treated with any drug targeting TRβ or with any drug being tested as therapy for X-ALD AMN form within the past 30 days before screening * History or presence of clinically significant acute or unstable hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological or oncological that in the opinion of the investigator would pose a significant risk for the subject * Subject has untreated primary adrenal insufficiency based on morning plasma cortisol and ACTH at screening * Lorenzo's Oil. Currently taking Lorenzo's Oil or erucic acid containing product, or other lipid lowering agent known to effect VLCFA levels
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs) | 28 days | Evaluate the safety and tolerability of multiple oral doses of VK0214 in subjects with AMN |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the Pharmacokinetics of VK0214 | 28 days | Pharmacokinetic profile of VK0214 by measuring Peak Plasma Concentration (Cmax) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Evaluate plasma VLCFAs changes | 28 days | Evaluate the efficacy of VK0214 on lowering plasma levels of VLCFAs in subjects with AMN |
Countries
France, Germany, Italy, United Kingdom, United States
Outcome results
None listed